You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
NEW YORK – Qiagen and Exosome Diagnostics, a subsidiary of Minneapolis-based Bio-Techne, said this week that they are developing a new workflow that integrates digital PCR and exosome-based liquid biopsy to detect bladder cancer mutations in urine samples.
360Dx Premium gives you: ✔ Full site access ✔ Interest-based email alerts ✔ Access to archives
Never miss another important industry story.
Try 360Dx Premium now.
You may already have institutional access!
Check if I qualify.
Already a 360Dx or GenomeWeb Premium member?Login Now.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.